Phase 3 trial shows extended PFS and OS accompanied by greater toxicity.
ONCOLOGY
Fully funded by 
Content independently selected
-
Adding chemotherapy to gefitinib boosts survival in EGFR+ NSCLC -
NICE approves dacomitinib for NSCLC Dacomitinib is recommended for untreated locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer
-
Use of prophylactic cranial irradiation drops sharply in SCLC Publication in 2017 showed no survival benefit vs MRI surveillance
-
NSCLC: step counts can help evaluate fitness for chemoradiation Physically active patients had better survival and lower hospitalization rates.
-
New lung cancer treatment option approved by NICE The decision is open to appeal until 22 August 2019
-
NSCLC: European consensus report defines oligometastatic disease Experts provide a uniform definition and diagnostic criteria.
-
EGFR+ NSCLC: no benefit for bevacizumab with frontline erlotinib Phase 2 study fails to meet primary or secondary survival endpoints.
-
Add-on WBRT extends survival with NSCLC brain metastases Significant benefit achieved by adding whole-brain radiotherapy to EGFR-TKIs.
-
High-risk patients show low interest in lung cancer screening More education needed to support informed patient decision-making.
-
NSCLC: lower cardiac dose constraints needed for radiation treatment One in 4 patients receive doses of more than 20 Gy.
-
NSCLC: low-dose afatinib does well in phase 2 study 30% of patients had grade 3 or higher adverse events.
-
EGFR+ NSCLC: adding targeted therapy to ACT prolongs survival Meta-analysis supports OS, DFS benefit.
-
High-dose SABR offers survival advantage in lung SCC No additional benefit over lower doses in adenocarcinoma.
-
NSCLC: no benefit for combining maintenance pemetrexed, bevacizumab Combination increases toxicity with no survival advantage over either drug alone.